Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01588678 · ClinicalTrials.gov registry record · Phase 1
A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01588678 is a Phase 1 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 32 participants.
The verdict
NCT01588678, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
DS-3078a will be evaluated as a single agent in subjects with advanced solid tumor malignancies or lymphomas refractory to standard treatment or for which no standard treatment is available.
Interventions
- DRUG DS-3078a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01588678
The ClinicalTrials.gov registry entry for NCT01588678 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DS-3078a is the first listed.
NCT01588678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01588678 about?
NCT01588678 is a clinical study titled "A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas". DS-3078a will be evaluated as a single agent in subjects with advanced solid tumor malignancies or lymphomas refractory to standard treatment or for which no standard treatment is available.
What is the current status of trial NCT01588678?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2012-04. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01588678?
The interventions under investigation include: DS-3078a (DRUG).
Who is sponsoring clinical trial NCT01588678?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.